rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Opko Health, Inc.

OPK · Nasdaq

Health CareBiotechnologyJust started moving

OPK stood above a rising 150-day average in 13 of the last 52 weekly readings, including each of the last 10 weeks. It is 19.3% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
10 in a row
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$3.2M
Insider sales, 12 months
$0
Officials’ trades on record
3
Institutions holding
217 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

3 disclosed lines: House 3, Senate 0, executive 0; 2 people.

WhoDidAmountTraded
Carlos Curbelo House: U.S. House ClerkFL26bought$1k–$15k26 Sep 2017filed 3 Oct 2017
Carlos Curbelo House: U.S. House ClerkFL26bought$1k–$15k2 Mar 2017filed 2 Mar 2017
Carlos Curbelo House: U.S. House ClerkFL26bought$1k–$15k7 Feb 2017filed 7 Feb 2017

Insiders

Buy orders, 12 months6
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
John A. PaganelliDirectorbought10,000at $1.1420 Mar 2026filed 20 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders217-2 on the quarter
New · exited27 · 31
Reported value$307.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Rubric Capital Management LPunchanged · filed 14 Aug 202647,791,243$71.7M00.0%
BlackRock, Inc.added · filed 7 Aug 202636,978,893$55.5M+746,670+2.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202614,968,930$22.5M+469,766+3.2%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 202614,934,924$22.4M+165,205+1.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202611,581,027$17.4M+279,526+2.5%
STATE STREET CORPadded · filed 7 Aug 202610,309,070$15.5M+807,693+8.5%
GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 20267,035,492$10.6M-639,534−8.3%
UBS Group AGreduced · filed 13 Aug 20265,006,284$7.5M-1,065,148−17.5%
Whitefort Capital Management, LPadded · filed 14 Aug 20264,511,412$6.8M+258,072+6.1%
NORTHERN TRUST CORPadded · filed 13 Aug 20263,756,163$5.6M+136,817+3.8%
31 Mar 2023 – 30 Jun 2026
188208228Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Adam Logal Company insiderSr. Vice President, CFO · last 24 Jul 20264 · 10
Steven D. Rubin Company insiderExecutive VP-Administration · last 24 Jul 202619 · 2
Alice Lin-Tsing Yu Company insiderDirector · last 18 Jun 20260 · 0
John A. Paganelli Company insiderDirector · last 18 Jun 202620 · 2
Prem A. Lachman Company insiderDirector · last 18 Jun 20260 · 0
Richard C. Pfenniger Jr. Company insiderDirector · last 18 Jun 20265 · 0
Roger Medel Company insiderDirector · last 18 Jun 20260 · 0
Subbarao Uppaluri V Company insiderDirector · last 18 Jun 20267 · 0
Frost Gamma Investments Trust Company insider10% owner · last 21 Nov 2025708 · 0
Phillip Et Al Frost Company insiderCEO & Chairman · last 31 Oct 2025802 · 0
Elias A. Zerhouni Company insiderVice Chairman and President · last 27 May 20252 · 0
Gary J. Nabel Company insiderChief Innovation Officer · last 27 May 20255 · 0

Same industry

MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
XNCR XencorLeading+44%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202533.9%
Operating profit marginFY 2025 · to 31 Dec 2025-19.3%
Free cash flow marginFY 2025 · to 31 Dec 2025-31.4%
Return on capital employedFY 2025 · to 31 Dec 2025-6.6%
Debt to equityFY 2025 · to 31 Dec 20250.54×
Research spendFY 2025 · to 31 Dec 202520.4%
Revenue growthFY 2025 · to 31 Dec 2025300%
Earnings per share growthFY 2025 · to 31 Dec 2025-233%
Share count trendFY 2025 · to 30 Jan 20261.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$364.4M
Free cash flowFY 2025 · to 31 Dec 2025−$190.8M

Analyst forecasts

No analyst forecasts yet.